Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Brugia malayi | oxidoreductase, short chain dehydrogenase/reductase family protein | 0.0012 | 0.0291 | 0.1732 |
Loa Loa (eye worm) | hypothetical protein | 0.0011 | 0.0192 | 0.1145 |
Entamoeba histolytica | 3-oxoacyl-(acyl-carrier protein) reductase, putative | 0.0012 | 0.0291 | 0.5 |
Trypanosoma brucei | pteridine reductase 1 | 0.0012 | 0.0291 | 0.5 |
Schistosoma mansoni | dihydropteridine reductase | 0.0012 | 0.0291 | 0.1554 |
Trypanosoma brucei | beta-ketoacyl-ACP reductase | 0.0012 | 0.0291 | 0.5 |
Trichomonas vaginalis | voltage and ligand gated potassium channel, putative | 0.0034 | 0.1542 | 0.1542 |
Plasmodium falciparum | enoyl-acyl carrier reductase | 0.0182 | 1 | 1 |
Brugia malayi | Voltage-gated potassium channel, EAG (KCNH1)-related. C. elegans egl-2 ortholog | 0.0011 | 0.0192 | 0.1145 |
Loa Loa (eye worm) | retinol dehydrogenase 12 | 0.0012 | 0.0291 | 0.1732 |
Loa Loa (eye worm) | hypothetical protein | 0.0032 | 0.1403 | 0.8354 |
Trypanosoma cruzi | beta-ketoacyl-ACP reductase | 0.0012 | 0.0291 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0012 | 0.0291 | 0.1732 |
Echinococcus granulosus | 3 oxoacyl acyl carrier protein reductase | 0.0012 | 0.0291 | 0.1732 |
Trypanosoma brucei | oxidoreductase-like protein | 0.0012 | 0.0291 | 0.5 |
Echinococcus multilocularis | 3 oxoacyl acyl carrier protein reductase | 0.0012 | 0.0291 | 0.1732 |
Onchocerca volvulus | 0.0012 | 0.0291 | 0.5 | |
Schistosoma mansoni | voltage-gated potassium channel | 0.0011 | 0.0192 | 0.1028 |
Leishmania major | oxidoreductase-like protein | 0.0012 | 0.0291 | 0.5 |
Trypanosoma cruzi | oxidoreductase-like protein, putative | 0.0012 | 0.0291 | 0.5 |
Leishmania major | pteridine reductase 1 | 0.0012 | 0.0291 | 0.5 |
Onchocerca volvulus | 0.0012 | 0.0291 | 0.5 | |
Brugia malayi | Voltage-gated potassium channel, HERG (KCNH2)-related. C. elegans unc-103 ortholog | 0.0037 | 0.168 | 1 |
Echinococcus granulosus | potassium voltage gated channel subfamily H | 0.0011 | 0.0192 | 0.1145 |
Trichomonas vaginalis | hypothetical protein | 0.0182 | 1 | 1 |
Echinococcus granulosus | voltage gated potassium channel | 0.0011 | 0.0192 | 0.1145 |
Leishmania major | dehydrogenase/oxidoreductase-like protein | 0.0012 | 0.0291 | 0.5 |
Toxoplasma gondii | enoyl-acyl carrier reductase ENR | 0.0182 | 1 | 1 |
Wolbachia endosymbiont of Brugia malayi | enoyl-ACP reductase | 0.0182 | 1 | 1 |
Mycobacterium tuberculosis | NADH-dependent enoyl-[acyl-carrier-protein] reductase InhA (NADH-dependent enoyl-ACP reductase) | 0.0182 | 1 | 1 |
Mycobacterium ulcerans | enoyl-(acyl carrier protein) reductase | 0.0182 | 1 | 1 |
Schistosoma mansoni | voltage-gated potassium channel | 0.004 | 0.1872 | 1 |
Brugia malayi | oxidoreductase, short chain dehydrogenase/reductase family protein | 0.0012 | 0.0291 | 0.1732 |
Loa Loa (eye worm) | oxidoreductase | 0.0012 | 0.0291 | 0.1732 |
Schistosoma mansoni | 3-oxoacyl-[ACP] reductase | 0.0012 | 0.0291 | 0.1554 |
Mycobacterium leprae | NADH-DEPENDENT ENOYL-[ACYL-CARRIER-PROTEIN] REDUCTASE INHA (NADH-DEPENDENT ENOYL-ACP REDUCTASE) | 0.0182 | 1 | 1 |
Echinococcus granulosus | potassium voltage gated channel subfamily H | 0.0037 | 0.168 | 1 |
Schistosoma mansoni | voltage-gated potassium channel | 0.0011 | 0.0192 | 0.1028 |
Echinococcus multilocularis | voltage gated potassium channel | 0.0011 | 0.0192 | 0.1145 |
Leishmania major | 3-oxoacyl-ACP reductase, putative | 0.0012 | 0.0291 | 0.5 |
Echinococcus multilocularis | potassium voltage gated channel subfamily H | 0.0011 | 0.0192 | 0.1145 |
Schistosoma mansoni | voltage-gated potassium channel | 0.004 | 0.1872 | 1 |
Plasmodium vivax | enoyl-acyl carrier protein reductase | 0.0182 | 1 | 1 |
Trypanosoma cruzi | beta-ketoacyl-ACP reductase | 0.0012 | 0.0291 | 0.5 |
Echinococcus multilocularis | potassium voltage gated channel subfamily H | 0.0037 | 0.168 | 1 |
Loa Loa (eye worm) | 3-hydroxyacyl-CoA dehydrogenase type II | 0.0012 | 0.0291 | 0.1732 |
Loa Loa (eye worm) | voltage and ligand gated potassium channel | 0.0037 | 0.168 | 1 |
Leishmania major | dehydrogenase/oxidoreductase-like protein | 0.0012 | 0.0291 | 0.5 |
Trichomonas vaginalis | voltage and ligand gated potassium channel, putative | 0.0034 | 0.1542 | 0.1542 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
GI50 (functional) | -4.383 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the SK-MEL-5 Melanoma cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4.08 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the UO-31 Renal cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the SN12C Renal cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the NCI-H23 Non-Small Cell Lung cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the ACHN Renal cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the HOP-92 Non-Small Cell Lung cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
GI50 (functional) | -4 | PUBCHEM_BIOASSAY: NCI human tumor cell line growth inhibition assay. Data for the SF-539 Central Nervous System cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.